Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia: Cochrane systematic review
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Rituximab, Ofatumumab and Other Monoclonal anti-CD20 Antibodies for Chronic Lymphocytic Leukaemia: Cochrane Systematic Review." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/437054/all/Imipramine_for_neuropathic_pain_in_adults:_Cochrane_systematic_review. Accessed 19 April 2024.
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia: Cochrane systematic review. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437054/all/Imipramine_for_neuropathic_pain_in_adults:_Cochrane_systematic_review. Accessed April 19, 2024.
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia: Cochrane systematic review. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/437054/all/Imipramine_for_neuropathic_pain_in_adults:_Cochrane_systematic_review
Rituximab, Ofatumumab and Other Monoclonal anti-CD20 Antibodies for Chronic Lymphocytic Leukaemia: Cochrane Systematic Review [Internet]. In: Cochrane Abstracts. [cited 2024 April 19]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/437054/all/Imipramine_for_neuropathic_pain_in_adults:_Cochrane_systematic_review.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia: Cochrane systematic review
ID - 437054
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/437054/all/Imipramine_for_neuropathic_pain_in_adults:_Cochrane_systematic_review
DB - Evidence Central
DP - Unbound Medicine
ER -